Welcome to our dedicated page for Ulta Beauty SEC filings (Ticker: ULTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ulta Beauty, Inc. (NASDAQ: ULTA) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its operations as a specialty beauty retailer. As a Delaware corporation with common stock listed on The NASDAQ Global Select Market under the symbol ULTA, the company submits annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, along with exhibits and other required disclosures.
Through these SEC filings, Ulta Beauty reports information on its financial condition, results of operations, risk factors, governance and executive compensation. For example, recent Forms 8-K have disclosed quarterly financial results, including net sales, comparable sales, gross profit and operating income, as well as material events such as Board appointments, executive transitions in the Chief Financial Officer role, adoption of an Executive Severance Plan and the planned conclusion of the Ulta Beauty at Target partnership. Other filings reference the company’s Executive Change in Control and Severance Plan and provide details on compensation arrangements for senior leaders.
For investors analyzing ULTA, the 10-K and 10-Q filings are central sources for segment performance, discussion of the Ulta Beauty Unleashed strategy, and summaries of risks related to macroeconomic conditions, consumer spending, competition, supply chain operations, cybersecurity, brand relationships and international expansion. Current reports on Form 8-K highlight specific events such as leadership changes, strategic agreements, and updates tied to earnings releases.
On this SEC filings page, users can access Ulta Beauty’s regulatory disclosures as they are made available through EDGAR. AI-powered tools can help summarize lengthy documents, highlight key sections and clarify complex topics such as executive severance arrangements, equity compensation plans and changes in governance structure. Filings related to insider roles, such as those that identify principal financial and accounting officers, can also be reviewed to understand how Ulta Beauty’s leadership and oversight evolve over time.
Ulta Beauty, Inc. has put a new Executive Severance Plan in place for its executive officers. This plan applies when an executive is involuntarily terminated without “Cause,” as defined in the plan, and not in connection with a change in control, death, or disability, which are handled separately.
The company’s existing Executive Change in Control and Severance Plan, originally adopted in 2017, will continue to govern qualifying terminations that occur in connection with a change in control. The new severance plan replaces prior severance protections for executive officers, such as individual letters or other plans, except for protections that are specifically provided under the change in control plan.
Ulta Beauty, Inc. director Catherine Ann Halligan reported a change in her holdings of the company’s common stock. On 12/15/2025, a transaction coded “G” (a bona fide gift) shows that 340 shares of common stock were disposed of at a price of $0, indicating the shares were given away rather than sold. Following this gift, she beneficially owns 2,060 shares of Ulta Beauty common stock in direct ownership.
Ulta Beauty (ULTA) appointed Christopher DelOrefice as Chief Financial Officer, and as principal financial and accounting officer, effective December 5, 2025. He joins from Becton Dickinson, following more than two decades in senior finance roles at Johnson & Johnson. Interim CFO Christopher Lialios will return to his role as Senior Vice President, Controller.
Compensation includes a $980,000 annual base salary. Beginning in fiscal 2026, he is eligible for an annual cash incentive with a target of 125% of base salary (maximum 200% of target) and participation in the long‑term incentive program with a 2026 target grant value of 450% of base salary (expected March 2026), split evenly between RSUs vesting March 15, 2029, and stock options vesting annually starting March 15, 2027. Sign‑on awards include $1,000,000 cash (subject to one‑year repayment if he resigns or is terminated for cause), RSUs valued at $1,100,000 vesting on the first anniversary, and RSUs valued at $2,200,000 vesting on the second anniversary, expected in December 2025. He will receive relocation support for 12 months and up to $20,000 in attorneys’ fees.
Form 144 notice for Ulta Beauty (ULTA) shows a proposed sale of 690 shares of common stock to be executed through Charles Schwab on 09/19/2025 with an aggregate market value of $369,019. The filer reports those 690 shares were acquired the same day via an employee stock option exercise and the exercise was a cashless exercise with broker payment.
The filing also discloses a prior sale by the same account: 1,525 shares sold on 09/11/2025 for gross proceeds of $791,994. The notice includes the standard representation that the seller is not aware of any material nonpublic information about the issuer.
Ulta Beauty, Inc. (ULTA) filed a Form 144 notifying intent to sell securities under Rule 144. The filer intends to sell 1,525 shares of common stock on or about 09/11/2025 through Charles Schwab & Co., Inc. The reported aggregate market value of the shares to be sold is $791,994.00, with 44,838,364 shares outstanding. The shares were acquired the same day, 09/11/2025, via an employee stock option exercise, and the payment method is listed as a broker payment for cashless exercise. No sales by the reporting person in the prior three months were reported. The notice includes the usual certification that the seller is not aware of undisclosed material adverse information about the issuer.
Mike C. Smith, a director of Ulta Beauty, Inc. (ULTA), reported a sale of 500 shares of ULTA common stock on 09/04/2025 at a reported price of $528.43 per share. After the sale, the filing shows Mr. Smith beneficially owned 2,263 shares directly. The Form 4 is signed by an attorney-in-fact on 09/08/2025.
Form 144 filed for ULTA. The filer notifies a proposed sale of 500 shares of Ulta Beauty common stock through Charles Schwab & Co., Inc. with an aggregate market value of $264,215.00, an approximate sale date of 09/04/2025, and the securities exchange listed as NASDAQ. The filing shows total shares outstanding of 44,838,364. The 500 shares were acquired as equity compensation: 67 shares lapsed 09/19/2020 and 433 shares lapsed 06/03/2021, both from Ulta Beauty. The filer reports no securities sold in the past three months and signs the notice attesting no undisclosed material adverse information.
Stephanie Lee Landry, a director of Ulta Beauty, Inc. (ULTA), acquired 277 restricted stock units on 09/01/2025. The Form 4 reports the grant as an acquisition (code A) at no cash price ($0). The filing shows 277 shares beneficially owned following the transaction in a direct ownership form. The RSUs are described in the explanation as vesting 100% on 09/01/2026. The Form 4 was signed by an attorney-in-fact on 09/03/2025. No derivatives, option exercises, cash purchases, or sales are reported in this filing.
Ulta Beauty director Martin Brok received a grant of 277 restricted stock units (RSUs) on 09/01/2025, recorded as a non‑derivative acquisition at a grant price of $0. After the grant, the reporting person beneficially owned 1,277 shares of Ulta Beauty common stock in a direct form. The RSUs vest 100% on 09/01/2026, per the form's explanation. The Form 4 was filed by a single reporting person and signed by an attorney‑in‑fact on 09/03/2025. This disclosure documents a routine equity compensation award to a director and the resulting change in direct beneficial ownership.
FAQ
What is the current stock price of Ulta Beauty (ULTA)?
What is the market cap of Ulta Beauty (ULTA)?
